Endocrinology Today—March 10, 2026

LucidQuest

44 minutes ago

This week’s Endocrinology update highlights regulatory progress in osteoporosis treatments, evolving clinical development strategies, new evidence in bone health, diabetes therapy advances, and emerging research across metabolic and reproductive disorders.

In Today’s Newsletter

Dive deeper

💉 Zandoriah gets EU committee backing for osteoporosis [1] [EU • 04 Mar 2026]

https://gabionline.net/biosimilars/news/ema-recommends-approval-for-teriparatide-biosimilar-zandoriah
Context: CinnaGen’s Zandoriah is a teriparatide biosimilar referencing Eli Lilly’s Forteo/Forsteo for osteoporosis.
Key point: EMA’s CHMP adopted a positive opinion recommending EU marketing authorization for Zandoriah; submitted data showed comparable quality, safety, and efficacy to Forsteo.
Implication: Introduces competition that may affect pricing and formulary access.

🦴 Entera Bio streamlines Phase 3 plan for oral EB613 [2] [US • 04 Mar 2026]

https://in.investing.com/news/company-news/entera-bio-submits-streamlined-phase-3-protocol-for-oral-osteoporosis-drug-93CH-5272344
Context: Entera Bio’s EB613 is an oral PTH tablet for postmenopausal osteoporosis; the planned Phase 3 study is randomized, double-blind, placebo-controlled, with 750 women.
Key point: The FDA submission proposes a 12-month primary endpoint for total hip bone mineral density, replaces a multi-tablet candidate with a single-tablet formulation, and could shorten development timelines.
Implication: May influence prescriber choice and payer reviews pending full data.

🩹 Transdermal estrogen leads in FHA-related bone loss [3] [UK • 04 Mar 2026]

https://www.medscape.com/viewarticle/transdermal-hrt-superior-oral-meds-fha-related-bone-loss-2026a10006nb
Context: A network meta-analysis of 13 randomized trials assessed pharmacologic options for women with functional hypothalamic amenorrhea and low bone mineral density risk.
Key point: Transdermal HRT improved lumbar spine and femoral neck BMD versus placebo/no intervention, while oral HRT and combined oral contraceptives did not show significant benefit across BMD sites.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🤖 Knee X-ray AI model improves osteoporosis detection [4] [04 Mar 2026]

https://conexiant.com/endocrinology/articles/ai-boosts-knee-xray-osteoporosis-detection/
Context: Korean researchers evaluated BONE-Net, a hybrid model combining DenseNet169, Vision Transformer, and an attention module on 372 knee radiographs.
Key point: On an independent 72-image test set, BONE-Net reached 86.1% accuracy and 94.7% specificity, outperforming several retrained deep-learning comparators in this dataset.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧪 Helmholtz Munich targets early-stage adult type 1 diabetes [5] [Germany • 02 Mar 2026]

https://www.helmholtz-munich.de/en/newsroom/news-all/artikel/helmholtz-munich-secures-funding-to-investigate-early-stage-type-1-diabetes-in-adults
Context: Breakthrough T1D awarded up to US$900,000 to support adult early-stage type 1 diabetes research using NAKO and Babydiab/Babydiet datasets.
Key point: The project will examine which islet autoantibodies and diagnostic criteria best identify early-stage T1D in adults, including analysis of more than 75,000 NAKO participants.
Implication: May expand screening, initiation, and follow-up at scale.

🧫 Akkermansia probiotic shows PCOS signal in rats [6] [03 Mar 2026]

https://www.the-microbiologist.com/news/akkermansia-muciniphila-probio-therapy-promotes-arginine-biosynthesis-and-reverses-reproductive-impairments-in-polycystic-ovary-syndrome-rats/8214.article
Context: In a DHEA-induced PCOS rat model, Akkermansia muciniphila PROBIO was tested alongside microbiome and metabolomic analyses. Key point: The probiotic improved reproductive and metabolic features in rats, with mechanistic data pointing to enhanced arginine biosynthesis and a possible role for L-arginine.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💉 Once-weekly efsitora matches daily basal insulin in T2D [7] [05 Mar 2026]

https://www.pharmacytimes.com/view/once-weekly-insulin-efsitora-demonstrates-comparable-efficacy-to-daily-basal-insulin-in-type-2-diabetes
Context: A systematic review and meta-analysis pooled randomized trials comparing Eli Lilly’s once-weekly insulin efsitora alfa with once-daily basal insulin in adults with type 2 diabetes.
Key point: Efsitora showed similar overall glycemic efficacy, a small HbA1c advantage at 52 weeks, lower weekly insulin dose, and a broadly comparable safety profile.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 Semaglutide patent loss draws Indian generics into GLP-1 race [8] [India • 03 Mar 2026]

https://www.fortuneindia.com/business-news/semaglutide-patent-loss-opens-up-a-6-billion-opportunity-for-indian-generic-drug-makers/130901
Context: Fortune India reports expected patent loss for semaglutide in several markets, with multiple Indian manufacturers preparing launches.
Key point: Sun Pharma, Dr Reddy’s, Zydus, Lupin, Natco and others are positioning generic semaglutide products for diabetes and weight management markets, with price declines anticipated by the source.
Implication: Introduces competition that may affect pricing and formulary access.

Why It Matters

Bone health is driving both brand innovation and follow-on competition, from oral PTH development [2] to teriparatide biosimilars in Europe [1].
Evidence in women with functional hypothalamic amenorrhea may shift prescribing away from oral estrogen approaches toward transdermal regimens [3].
Diabetes care is broadening across prevention, treatment, and delivery models, including adult T1D screening research [5] and weekly basal insulin [7].
AI-enabled imaging tools such as BONE-Net could widen opportunistic osteoporosis detection, but validation remains early and dataset-limited [4].
The GLP-1 market is entering a new access phase in selected countries as semaglutide patent cliffs attract generic manufacturers [8].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What is Zandoriah, and why does the CHMP opinion matter?

Zandoriah is CinnaGen’s teriparatide biosimilar for osteoporosis. A positive CHMP opinion is a key step toward European Commission approval and potential EU market entry [1].

What changed in Entera Bio’s EB613 Phase 3 program?

Entera Bio submitted a revised FDA protocol that uses a 12-month total hip BMD primary endpoint and advances a single-tablet oral formulation directly into Phase 3 [2].

For FHA-related bone loss, what did the meta-analysis favor?

The analysis favored transdermal estrogen HRT over oral HRT and combined oral contraceptives for bone mineral density outcomes, especially at the lumbar spine and femoral neck [3].

Is BONE-Net ready for clinical use in osteoporosis screening?

The reported results are promising, but the study used a small knee radiograph dataset and did not include clinical variables such as age, sex, or BMD, so external validation is still needed [4].

What is Helmholtz Munich trying to prove in adult type 1 diabetes?

The team is studying whether islet autoantibodies and related criteria can identify early-stage T1D in adults, using large population and longitudinal cohorts [5].

What is the key takeaway on once-weekly efsitora?

The meta-analysis suggests efsitora can deliver glycemic control comparable to daily basal insulin, with a modest HbA1c benefit at 52 weeks and similar safety overall [7].

Entities / Keywords

Zandoriah (CinnaGen; teriparatide biosimilar; Forteo; Forsteo; osteoporosis)
EB613 (Entera Bio; oral PTH tablet; oral teriparatide approach; postmenopausal osteoporosis)
Functional hypothalamic amenorrhea (FHA; transdermal HRT; oral HRT; combined oral contraceptive pill; COCP)
BONE-Net (osteoporosis AI; knee radiographs; DenseNet169; Vision Transformer)
Helmholtz Munich (Breakthrough T1D; NAKO; Babydiab; Babydiet; islet autoantibodies)
Akkermansia muciniphila PROBIO (PCOS; probiotic; arginine biosynthesis; L-arginine)
Insulin efsitora alfa (Eli Lilly; once-weekly basal insulin; type 2 diabetes)
Semaglutide (Ozempic; Wegovy; Sun Pharma; Dr Reddy’s; Zydus; GLP-1 generics)